Dr Anjana Anand Publications
Peer-Reviewed Publications
- The Nottingham Experience: Topotecan for Relapsed Ovarian Cancer: Anand A, Chan S Y;* Clinical Oncology, 2004 Dec; 16(8):543-8 – This study evaluated the use of Topotecan in relapsed ovarian cancer in accordance with the National Institute of Clinical Excellence Guidance (2001).
- External Beam Radiotherapy for Extensive Genital Condyloma Acuminata: Dhadda AS, Anand A, Boynton C, Chan S;* Clinical Oncology, 2008 Feb; 20(1):91-2 – This research explored the role of external beam radiotherapy in selected patients with extensive genital condyloma acuminata.
- Objective Responses to Neo-Adjuvant Carboplatin–Paclitaxel in Ovarian Cancer (ICON8): Morgan RD, McNeish I, Cook A, James EC, Anand A, et al.;* The Lancet Oncology, 2021 Feb; 22(2):277-288 – This post-hoc exploratory analysis of a Phase III trial assessed neo-adjuvant regimens for ovarian, fallopian tube, or primary peritoneal carcinoma.
- PARAGON Trial: Phase II Study of Anastrozole in Low-Grade Endometrial Stromal Sarcomas: Friedlander M, Benson C, Anand A, et al.;* Gynaecologic Oncology, 2021 April; 161(1):160-165
Publications
- 06 Nov 2025 https://doi.org/10.3390/cancers172113591. Cancers 2025,17(21),3591
The real-world impact of PARP Inhibitor Maintenance Therapy in High grade serous Tubo-Ovarian and Peritoneal cancers.
Maryam Al-Ani, Bahaaeldin Baraka, Navin Mathiyalagan, Muhammad Adeel Sarwar, Avinash Segaran, Wafaa Abuzahra, Alayna Radford, Kersty Buxton, Lalith Seneviratne, Santhanam Sundar, Anjana Anand, David Nunns, Karin Williamson, Ben Wormald, Ketankumar Gajjar and Srinivasan Madhusudan.
- 02 May 2025 https://www.ejcancer.com/article/S0959-8049(25)00156-X/fulltext . European Journal of Cancer, volume 220, 2025, 115375
Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial
G. Eminowicz, S. Vaja, D. Gallardo, C. Kent, M. Panades, T. Mathew, A. Anand, J. Forrest, M. Adusumalli, A. Chan, A.M. Hacker, A. Hackshaw, J.A. Ledermann, M. McCormack
- October 14, 2024 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01438-7/fulltext www.lancet.com
Mary McCormack, G Eminowicz, D Gallardo,P Diez, L Farrelly, C Kent, E Hudson, M Panades, T Mathew, Anjana Anand, M Persic, J Forrest, R Bhana , N Reed et al ..
Induction chemotherapy followed by standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicenter, randomized phase 3 trial.
- October 26, 2023; Cancers (Basel);15(21):5164. doi: 10.3390/cancers15215164. PMID: 37958338; PMCID: PMC10647609.
Tang H, Yeo D, De Souza K, Ahmad O, Shafiq T, Ofor O, Anand A, Karim S, Khan S, Madhusudan S.
Clinical Impact of CDK4/6 Inhibitors in De Novo or PR- or Very Elderly Post-Menopausal ER+/HER2- Advanced Breast Cancers. Cancers (Basel). 2023 Oct 26;15(21):5164. doi: 10.3390/cancers15215164. PMID: 37958338; PMCID: PMC10647609
Books and Book Chapters
- Systemic Therapies in Gynaecological Cancers
- Co-authored with Benjamin Masters; *Gynaecological Oncology for the MRCOG,* Cambridge Medicine, 2018.